Lenalidomide (Revlimid; Celgene Corporation, Summit, NJ) is an amino-substituted variant of thalidomide that belongs to a class of analogues known as immunomodulatory drugs.1 Preliminary data show that this drug is effective in treating newly diagnosed and relapsed multiple myeloma, as well as transfusion-dependent, low-risk myelodysplastic syndromes.2,3 We report a case of neutrophilic dermatosis of the hands in a patient receiving lenalidomide therapy.
Hoverson AR, Davis MDP, Weenig RH, Wolanskyj AP. Neutrophilic Dermatosis (Sweet Syndrome) of the Hands Associated With Lenalidomide. Arch Dermatol. 2006;142(8):1065-1086. doi:10.1001/archderm.142.8.1070-b